Geron (GERN) Long-Term Investments (2010 - 2026)
Geron's (GERN) quarterly Long-Term Investments came in at $26.7 million in Q1 2026, down 54.61% year-on-year from $58.8 million in Q1 2025, and down 35.37% quarter-over-quarter from $41.3 million in Q4 2025.
Geron (GERN) Long-Term Investments (2010 - 2026) Analysis & Trends
Geron has disclosed Long-Term Investments across 16 years of filings, most recently posting $26.7 million for Q1 2026.
- Long-Term Investments for Q1 2026 came in at $26.7 million, down 54.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.7 million (down 54.61% YoY), and the FY2025 annual result was $41.3 million, down 56.32% from the prior year.
- Long-Term Investments came in at $26.7 million for Q1 2026 at Geron, down from $41.3 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $94.5 million in Q4 2024 to a low of $10.9 million in Q1 2022.
- The 5-year median for Long-Term Investments is $40.2 million (2025), against an average of $43.3 million.
- Across the five-year window, Long-Term Investments tumbled 67.12% in 2022 and surged 182.91% in 2025, its largest moves.
- Geron's Long-Term Investments stood at $10.9 million in 2022, then soared by 295.6% to $43.3 million in 2023, then soared by 118.3% to $94.5 million in 2024, then sank by 56.32% to $41.3 million in 2025, then tumbled by 35.37% to $26.7 million in 2026.
- The last three Long-Term Investments figures came in at $26.7 million (Q1 2026), $41.3 million (Q4 2025), and $39.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Geron | 729,618.77 | 729,618.77 | - | 26.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.69 Mn |
| Dec 31, 2025 | 41.29 Mn |
| Sep 30, 2025 | 39.06 Mn |
| Jun 30, 2025 | 42.74 Mn |
| Mar 31, 2025 | 58.80 Mn |
| Dec 31, 2024 | 94.52 Mn |
| Sep 30, 2024 | 37.31 Mn |
| Jun 30, 2024 | 66.51 Mn |
| Mar 31, 2024 | 20.78 Mn |
| Dec 31, 2023 | 43.30 Mn |
| Sep 30, 2023 | 67.82 Mn |
| Jun 30, 2023 | 28.28 Mn |
| Mar 31, 2023 | 28.10 Mn |
| Mar 31, 2022 | 10.95 Mn |
| Dec 31, 2021 | 28.65 Mn |
| Sep 30, 2021 | 39.36 Mn |
| Jun 30, 2021 | 40.52 Mn |
| Mar 31, 2021 | 33.29 Mn |
| Dec 31, 2020 | 63.39 Mn |
| Sep 30, 2020 | 45.77 Mn |